# Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma

> **NCT03632135** · PHASE3 · COMPLETED · sponsor: **Cordgenics, LLC** · enrollment: 78 (actual)

## Conditions studied

- Recurrent Glioblastoma

## Interventions

- **DIAGNOSTIC_TEST:** ChemoID assay
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT03632135
- **Lead sponsor:** Cordgenics, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-20
- **Primary completion:** 2022-06-16
- **Final completion:** 2023-12-31
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2025-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03632135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03632135, "Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT03632135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*